Document is current
Any future updates will be listed below
-
Authors
Newby, Gregory A.
Yen, Jonathan S. https://orcid.org/0000-0002-9432-9450
Woodard, Kaitly J. https://orcid.org/0000-0002-5622-8069
Mayuranathan, Thiyagaraj
Lazzarotto, Cicera R. https://orcid.org/0000-0003-1093-0175
Li, Yichao https://orcid.org/0000-0001-5791-096X
Sheppard-Tillman, Heather https://orcid.org/0000-0002-9623-2812
Porter, Shaina N.
Yao, Yu
Mayberry, Kalin
Everette, Kelcee A.
Jang, Yoonjeong
Podracky, Christopher J.
Thaman, Elizabeth
Lechauve, Christophe
Sharma, Akshay https://orcid.org/0000-0003-3281-2081
Henderson, Jordana M.
Richter, Michelle F.
Zhao, Kevin T. https://orcid.org/0000-0003-3440-2094
Miller, Shannon M.
Wang, Tina
Koblan, Luke W. https://orcid.org/0000-0003-2814-4412
McCaffrey, Anton P.
Tisdale, John F.
Kalfa, Theodosia A. https://orcid.org/0000-0002-0426-9686
Pruett-Miller, Shondra M. https://orcid.org/0000-0002-3793-585X
Tsai, Shengdar Q. https://orcid.org/0000-0001-9161-3993
Weiss, Mitchell J. https://orcid.org/0000-0003-2460-3036
Liu, David R. https://orcid.org/0000-0002-9943-7557
- License Information
-
More Information
Article History
Received: 10 January 2021
Accepted: 4 May 2021
First Online: 2 June 2021
Competing interests
: G.A.N., K.A.E., M.F.R., K.T.Z., S.M.M., T.W., L.W.K., and D.R.L. have filed patent applications on aspects of base editing through the Broad Institute. D.R.L. is a consultant and equity owner of Beam Therapeutics, Prime Medicine, and Pairwise Plants (companies that use genome editing). M.J.W. is on advisory boards for Cellarity Inc., Novartis, and Forma Therapeutics, and is an equity owner of Beam Therapeutics. A.S. is a consultant for Spotlight Therapeutics and his institution receives clinical trial support for the conduct of sickle cell disease gene editing trials from Vertex Pharmaceuticals, CRISPR Therapeutics, and Novartis. J.S.Y. is an equity owner of Beam Therapeutics. The authors declare no non-financial competing interests.
